All Updates

All Updates

icon
Filter
Funding
Product updates
iOnctura includes oral TGF-β pathway inhibitor to its pipeline
Precision Medicine
May 3, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

May 3, 2023

iOnctura includes oral TGF-β pathway inhibitor to its pipeline

Funding
Product updates

  • Drug discovery company iOnctura exercised an exclusive option with Clavius Pharmaceuticals, adding the novel oral TGF-β pathway inhibitor, IOA-359, to its pipeline. The company also received a grant from Health Holland and KWF in collaboration with the University of Twente. iOnctura is solely responsible for global development and commercialization of the small molecule inhibitor.

  • The funding will be used for the development of IOA-359 and the characterization of resistance mechanisms.

  • iOnctura is a clinical-stage biotech company focused on developing selective cancer therapies that target critical tumor survival pathways. They are using data-driven precision oncology methods to design combination treatments that overcome resistance pathways. iOnctura has two candidates in mid-stage clinical development, IOA-244 and IOA-289, while IOA-359 is undergoing preclinical preparations. The company is headquartered in Amsterdam, with a subsidiary in Geneva.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.